SILICON VALLEY, Calif., Dec 3, 2019 — RSIP Vision, a global leader in artificial intelligence (AI), computer vision, and image processing technology, announced today that
The use of deep learning for analysis of multiplex IF has allowed for a much greater accuracy level for the correct phenotypic classification of cells. When combined with RSIP Vision‘s advanced nuclear detection capability, it allows for the simultaneous analysis of multiple florescent markers on a cell by cell basis. This tool is well suited for multiple applications, especially when using multiple markers to characterize distinct cell populations such as in immune-oncology and IBD.
New AI technologies by RSIP Vision are very powerful in analysis of tissues and histopathology. This complex task, which has been haunting for years the medical community, has now a very practical solution: deep learning gives very fruitful results to several challenges, like the segmentation of cells and nucleus and the classification of the cells according to the detected pathologies.
RSIP Vision’s oncology software combines detection of lesions and tumors in the human body with tracking those findings along CT scans performed during the research: in particular lung, lymph nodes and liver. These tools enable a quick and accurate assessment of the efficacy of the new treatment.
The golden standard for measuring tumors is the RECIST score. RSIP Vision developed an automated module to accurately measure the RECIST score from CT scans as well as the exact 3D volume of the tumors. Changes in volume are a reliable measure of the progression or remission of the tumor, enabling to evaluate the responsiveness of the treatment in a relatively short time.
Get in touch
Please fill the following form and our experts will be happy to reply to you soon